N.E.W. Advisory Services’s BridgeBio Pharma BBIO Stock Holding History

N.E.W. Advisory Services’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49K	Hold	20	–	–	﹤0.01%	844
2025 Q4	$1.53K	Hold	20	–	–	﹤0.01%	821
2025 Q3	$1.04K	Buy	+20	New	+$975	﹤0.01%	793

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

N.E.W. Advisory Services's BBIO Position: Q1 2026 in Review

N.E.W. Advisory Services held its BridgeBio Pharma (BBIO) position steady in Q1 2026 at 20 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #844.

N.E.W. Advisory Services first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.53K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

N.E.W. Advisory Services held 20 shares of BridgeBio Pharma worth $1.49K as of Q1 2026.
N.E.W. Advisory Services left its BridgeBio Pharma share count unchanged in Q1 2026.
BridgeBio Pharma made up ﹤0.01% of N.E.W. Advisory Services's portfolio in Q1 2026, its #844 holding.
N.E.W. Advisory Services first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
N.E.W. Advisory Services's BridgeBio Pharma position peaked at $1.53K in Q4 2025.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on N.E.W. Advisory Services's 13F filing for Q1 2026, filed 5 May 2026.